Department of Urology, School of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Cancer Discov. 2013 Oct;3(10):1099-102. doi: 10.1158/2159-8290.CD-13-0581.
Limited understanding of the functional link between multiple oncogenic pathways is a major barrier in the ongoing effort of cancer biologists to design an effective therapeutic approach to treat malignancies characterized by driver oncogenic network signals. In this issue of Cancer Discovery, Tan and colleagues elucidate a novel PDK1-PLK1-MYC signaling pathway connecting two fundamental oncogenic programs, phosphoinositide 3-kinase and MYC. They define the functional role for PDK1-PLK1-MYC signaling in cancer cell survival and tumor formation and show the therapeutic benefit of inhibiting PDK1 and PLK1 pharmacologically in cancer, tackling the most undruggable tumors defined by elevated levels of the MYC oncoprotein.
目前癌症生物学家正在努力设计一种有效的治疗方法来治疗以驱动致癌网络信号为特征的恶性肿瘤,但对多种致癌途径之间的功能联系的认识有限,这是一个主要障碍。在本期《Cancer Discovery》中,Tan 及其同事阐明了一个连接两个基本致癌程序——磷酸肌醇 3-激酶和 MYC 的新型 PDK1-PLK1-MYC 信号通路。他们定义了 PDK1-PLK1-MYC 信号在癌细胞存活和肿瘤形成中的功能作用,并显示了通过药理学抑制 PDK1 和 PLK1 在癌症中的治疗益处,解决了由高水平 MYC 癌蛋白定义的最具挑战性的肿瘤。